Eli Lilly and Company (NYSE: LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly ...
“In my experience and personally managing my own psoriasis, I’ve found consistent red-light therapy helps to reduce redness, soothe irritation, and support the skin’s recovery during flare-ups. While ...
Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company ...
ZORYVE ® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, ...
Eli Lilly and Company today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound ...
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...
Zoryve (roflumilast) is a prescription drug that’s used to treat plaque psoriasis, atopic dermatitis, and seborrheic dermatitis in adults and certain children. Zoryve comes as a topical cream or ...
Arcutis Biotherapeutics delivered a strong Q4 2025, with $127.5M in revenue and a GAAP EPS beat, driven by Zoryve's rapid ...
Max Homa opens up about joining the Free to Be Me campaign, sharing his personal health journey and encouraging others to seek proper care.
Johnson & Johnson's stock hits a 52-week high, but key drug patent risks and a lower Wall Street price target suggest downside. Learn more about JNJ stock here.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...
Patients with moderate‑to‑severe plaque psoriasis achieve greater relief from itching, skin pain, and scaling with bimekizumab vs secukinumab up to 3 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results